North America’s medical devices industry top deal activity in January 2021
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

North America’s medical devices industry saw a drop of 30.23% in deal activity during January 2021

22 Feb 2021

North America’s medical devices industry saw a drop of 30.23% in deal activity during January 2021, when compared with the last 12-month average, led by OptumInsight’s $13bn acquisition of Change Healthcare, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 60 medical devices industry deals worth $22.38bn were announced for the region in January 2021, against the 12-month average of 86 deals.

Of all the deal types, venture financing saw most activity in January 2021 with 27 transactions, representing a 45% share for the region.

In second place was M&A with 26 deals, followed by private equity deals with seven transactions, respectively capturing a 43.3% and 11.7% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $21.21bn, while venture financing and private equity deals totalled $936.83m and $233.21m, respectively.

North America medical devices industry deals in January 2021: Top deals

The top five medical devices deals accounted for 89.4% of the overall value during January 2021.

The combined value of the top five medical devices deals stood at $20.01bn, against the overall value of $22.38bn recorded for the month.

The top five medical devices industry deals of January 2021 tracked by GlobalData were:

1) OptumInsight’s $13bn acquisition of Change Healthcare

2) The $4.6bn acquisition deal with Cantel Medical by Steris

3) Boston Scientific’s $1.23bn acquisition of Preventice

4) The $635m acquisition of Capsule Technologies by Koninklijke Philips

5) Thermo Fisher Scientific’s acquisition of Mesa Biotech for $550m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.